News | Artificial Intelligence | April 07, 2025

Viz.ai Receives Edison Award for HCM Module

Honored for excellence and innovation in cardiovascular health diagnostics for hypertrophic cardiomyopathy module.

Viz HCM

April 4, 2025 — Viz.ai has been named an Award Winner in the 2025 Edison Awards, for the third year in a row.

Viz HCM, the company’s AI software solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), was recognized in the Health Medical & Biotech category and Cardiovascular Health Diagnostics and Monitoring subcategory. The Edison Awards, named after the American inventor Thomas Alva Edison, honor excellence in new product and service development, marketing, design and innovation. The awards are widely recognized as one of the premier accolades that companies can receive in the name of innovation and business success.

“We are honored to win our third, prestigious Edison Award, reaffirming our mission-critical work to transform AI-driven healthcare,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai. “HCM is an underdiagnosed condition that is the most commonly inherited cardiac disease, yet, unfortunately only 15% of these patients are diagnosed. The recognition of Viz HCM, which accelerates the patient identification and journey for this serious disease, validates our efforts to help clinicians to deliver faster and better care.”

Viz HCM uses artificial intelligence to analyze all 12-lead electrocardiograms (ECGs) from across a health system to identify suspected HCM cases, notify cardiology care teams and increase the likelihood that patients get the right follow-up and diagnosis. The Viz HCM module, developed as part of a multi-year funding agreement between Viz.ai and Bristol Myers Squibb, was granted De Novo approval by the FDA in August 2023, creating a new regulatory category for cardiovascular machine learning-based notification software. Recent data, presented at the American College of Cardiology meeting, demonstrated that Viz HCM successfully helped identify 574 HCM patients in a single major academic hospital (Cleveland Clinic) in a 9 month period, highlighting Viz HCM’s ability for more effective disease detection.1

All nominations are reviewed by the Edison Awards’ Steering Committee and an executive judging body. The panel is composed of more than 2,000 senior business executives and academics from the fields of product development, design, engineering, science, marketing and education, as well as past winners.

Winners were announced at the Edison Awards Gala on April 3, 2025 in Fort Myers, FL.

For more information on Viz HCM, visit https://www.viz.ai/hypertrophic-cardiomyopathy.

 

Real-World Artificial Intelligence–Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy. JACC: Clinical Electrophysiology. https://www.jacc.org/doi/10.1016/j.jacep.2025.02.024


Related Content

News | Artificial Intelligence

April 22, 2025 — Mount Sinai researchers studying hypertrophic cardiomyopathy (HCM) have calibrated an artificial ...

Home April 22, 2025
Home
News | Artificial Intelligence

April 16, 2025 — An artificial intelligence (AI) program trained to review images from a common medical test can detect ...

Home April 16, 2025
Home
News | Artificial Intelligence

March 3, 2025 — Microsoft Corp. has unveiled Microsoft Dragon Copilot, an AI assistant for clinical workflow that brings ...

Home March 03, 2025
Home
News | Artificial Intelligence

Feb. 25, 2025 — Heartflow, Inc., a provider of AI technology for coronary artery disease (CAD) management, recently ...

Home February 26, 2025
Home
News | Artificial Intelligence

Feb. 6, 2025 — Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung ...

Home February 10, 2025
Home
News | Artificial Intelligence

Feb. 4, 2025 — Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 ...

Home February 04, 2025
Home
News | Artificial Intelligence

Jan. 22, 2025 — Public Responsibility in Medicine and Research (PRIM&R) recently called for establishing clear ethical ...

Home January 23, 2025
Home
News | Artificial Intelligence

Jan. 22, 2025 -- HeartFlow, Inc., a provider of non-invasive artificial intelligence (AI) heart care solutions, and ...

Home January 23, 2025
Home
News | Artificial Intelligence

Dec. 4, 2024 – Cleerly has successfully closed its latest Series C extension funding round, raising a total of $106 ...

Home December 05, 2024
Home
News | Artificial Intelligence

Oct. 30, 2024 — HeartLung Technologies, a developer of AI tools for early detection of heart disease, lung cancer and ...

Home October 30, 2024
Home
Subscribe Now